The Wellness Files with Kari Beal
The federal government is fast-tracking some psychedelic-based medicines for research and development. Emergency physician Dr. Jonathan Leak explains how these therapies may work in the brain and if they’re safe. 00:00 — Fire captain recounts suicidal crisis; psilocybin changes his outlook and family life 00:36 — Intro: what psychedelics might do (neurotransmitters/neuroplasticity) and the safety question 00:54 — Why now: executive order to speed development; focus on treatment-resistant depression, PTSD, addiction 01:23 — Arizona psilocybin trial for first responders; content warning for sensitive topics 02:05 — Mark Herman’s story: chronic trauma, “fight or flight,” and seeking relief 03:01 — Research barriers from past criminalization; trial details and demand/waitlist 04:22 — Career risks/stigma for officers; underground use; dosing and safety concerns 05:01 — Black market concerns; funding push; hopes for right-to-try and guardrails as access expands 07:20 — Interview begins: Dr. Leak’s credentials; ketamine currently used in psychedelic therapy 08:15 — What drugs are discussed: psilocybin, ibogaine, methylone/MDMA 09:00 — Evidence/history; why these may help PTSD, depression, addiction 10:53 — How they may work: receptors + neuroplasticity + psychedelic experience; importance of therapy integration 12:36 — Brain connectivity shifts; new pathways; how psilocybin is dosed and how long sessions last 15:01 — Patents/formulations; molecule tweaks vs process patents 16:02 — MDMA/methylone differences; trauma processing and study outcomes; need for certified care 18:08 — Clinic model questions; side effects, monitoring, and scaling sessions safely
29 afleveringen
Reacties
0Wees de eerste die een reactie plaatst
Meld je nu aan en word lid van de The Wellness Files with Kari Beal community!